Semaglutide | Drugs | BNF | NICE
Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms
To cut through the static, you need the facts laid out plainly
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al
If youve been following the news around medications like semaglutide (Ozempic, Wegovy) , tirzepatide (Mounjaro, Zepbound) , and the newer retatrutide (still in clinical trials) , youve probably heard about their impressive results
Stakeholders Interviewed Primary interviews for this study involved: Manufacturers and suppliers in the market value chain Distributors, channel partners, and integrators End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market) Industry experts, technology specialists, consultants, and regulatory professionals Senior executives (CEOs, CTOs, VPs, Directors) and product managers Interview Process Interviews were conducted via: Structured and semi-structured questionnaires Telephonic and video interactions Email correspondences Expert consultation sessions Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation
